Anixa Biosciences Secures Key Patent for Breast Cancer Vaccine

In the ever-evolving landscape of biotechnology, Anixa Biosciences has made a significant stride forward with the issuance of US Patent No. 10,463,724 for its groundbreaking breast cancer vaccine technology. This patent, titled "Breast Cancer Vaccine," covers a method developed by Dr. Vincent Tuohy of the Cleveland Clinic, which aims to protect women from developing breast cancer by targeting a specific protein that reappears in many forms of the disease, particularly the lethal triple negative breast cancer (TNBC).



The implications of this patent are vast. Breast cancer remains one of the most prevalent and deadly forms of cancer, affecting millions of women worldwide. Traditional treatments, while effective in some cases, often come with significant side effects and are not always successful in preventing recurrence. Anixa Biosciences' approach, which harnesses the body's immune system to fight cancer, represents a paradigm shift in cancer prevention and treatment.

The patent is assigned to the Cleveland Clinic, with Anixa Biosciences holding the exclusive worldwide license. This licensing agreement provides Anixa with a significant competitive advantage, as it ensures that their technology is protected from imitation and competition. The company's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. This diversified approach to cancer treatment and prevention positions Anixa Biosciences as a forward-thinking company with a strong pipeline of innovative technologies.

The market implications of this patent are equally significant. The global cancer vaccine market is expected to grow at a compound annual growth rate (CAGR) of 11.3% from 2020 to 2027, reaching $13.7 billion by the end of the forecast period. Anixa Biosciences' breast cancer vaccine technology, with its unique approach to cancer prevention, could capture a significant share of this market. The company's strong intellectual property position, supported by a robust portfolio of patents and patent applications, further enhances its competitive advantage.

Investors are likely to view Anixa Biosciences' strong intellectual property position and innovative technologies favorably, potentially leading to increased investment and higher stock prices. The company's unique business model of partnering with world-renowned research institutions, such as the Cleveland Clinic, further enhances its credibility and potential for success. As stated by Dr. Amit Kumar, Chief Executive Officer of Anixa, "We are pleased that this key patent has been issued for technology, which we hope may eliminate breast cancer. This patent covers Dr. Tuohy's method of protecting women from developing breast cancer by vaccinating against a protein that is 'retired' from service after a woman has stopped lactating, only to reappear later in life in many forms of breast cancer, especially triple negative breast cancer (TNBC), the most lethal form of the disease. We look forward to progressing towards major breakthroughs in the prevention of breast cancer."

In summary, Anixa Biosciences' issuance of US Patent No. 10,463,724 for its breast cancer vaccine technology represents a significant milestone in the company's journey towards becoming a leader in cancer prevention and treatment. The patent's unique approach to cancer prevention, supported by a robust intellectual property portfolio and a diversified therapeutic portfolio, positions Anixa Biosciences well for potential success in the biotechnology sector. Investors and patients alike will be watching closely as the company continues to advance its innovative technologies towards commercialization.